You are here

Novartis

FDA expands use of Novartis MS drug to pediatric patients

Yahoo/Reuters

Sat, 05/12/18 - 11:35 am

Democratic senator opens probe into Novartis over its dealings with Trump’s attorney

Stat

Fri, 05/11/18 - 11:30 am

‘Not a good day for Novartis’: CEO tries to reassure employees amid fury over payments to Trump’s lawyer

Stat

Thu, 05/10/18 - 11:12 pm

Vasant Narasimham

Novartis, Durect renegotiate $293M painkiller deal after phase 3 failure

Fierce Biotech

Thu, 05/10/18 - 09:46 am

post-operative pain

clinical trials

Novartis paid Trump’s lawyer’s firm far more than any of its actual lobbyists

Stat

Thu, 05/10/18 - 09:13 am

healthcare reform

Novartis Actually Paid Michael Cohen $1.2 Million – For Nothing

CP Wire

Wed, 05/9/18 - 02:26 pm

healthcare reform

Novartis Actually Paid Michael Cohen $1.2 Million – For Nothing

Wed, 05/9/18 - 02:25 pm

healthcare reform

Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug

Fierce Biotech

Wed, 05/9/18 - 09:21 am

acute myeloid leukemia

Drugmaker Novartis plays down its deal with Trump’s lawyer, tying it to its former CEO

Marketwatch

Wed, 05/9/18 - 09:18 am

Vasant Narasimham

Novartis Paid $400,000 to Trump's Atty Michael Cohen According to Stormy Daniels' Lawyer

CP Wire

Tue, 05/8/18 - 08:44 pm

Novartis Paid $400,000 to Trump's Atty Michael Cohen According to Stormy Daniels' Lawyer

Tue, 05/8/18 - 10:17 pm

Aurobindo bids $1.6B for Novartis' U.S. dermatology generics: report

Fierce Pharma

Mon, 05/7/18 - 10:53 pm

FDA approves Novartis combo therapy for aggressive type of thyroid cancer

Reuters

Fri, 05/4/18 - 06:53 pm

anaplastic thyroid cancer

New approval sets up CAR-T showdown for Gilead, Novartis

Biopharma Dive

Wed, 05/2/18 - 10:00 pm

Gilead Sciences

Eyeing Eylea’s $5B sales, Novartis touts solid 12-week dosing data for its rival RTH258

Endpoints

Mon, 04/30/18 - 09:04 pm

wet age-related macular degeneration

4 Huge Pharma Deals in 4 Months Is Just the Beginning

Motley Fool

Sat, 04/28/18 - 12:18 pm

Juno Therapeutics

First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy

CP Wire

Wed, 04/25/18 - 10:29 pm

clinical trials

spinal muscular atrophy

Novartis CEO Vas Narasimhan is raising the bar on second-gen cancer drug studies

Endpoints

Sat, 04/21/18 - 12:44 pm

Novartis pads case for new MS blockbuster with disease-progression analysis

Fierce Pharma

Sat, 04/21/18 - 12:41 pm

multiple sclerois

Good news, Glaxo: Novartis' Advair copy definitely won't see the market this year

Fierce Pharma

Fri, 04/20/18 - 10:00 am

Pages